An interventional study of Experimental Infant formula and Infant formula thickened with locust bean gum in Gastroesophageal Reflux in Children, sponsored by United Pharmaceuticals. Recruiting at 12 sites in 4 countries. Open to participants aged 2 Weeks to 4 Months. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by United Pharmaceuticals · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Gastroesophageal Reflux with a site in France — 6 open to participants now, 7 under way, none of them phase 3. Gastroesophageal Reflux · France.
Among the 62 studies in Gastroesophageal Reflux with a site in France, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 with no phase, and was the 51st registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →6 of the 62 studies in Gastroesophageal Reflux with a site in France are open now. Recruiting first, the newest first:
United Pharmaceuticals · Sites in France
Ages up to 4 mo
Medtronic Cardiovascular · Sites in France, Denmark, Germany and 5 more countries
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 2 Weeks to 4 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 14 · Phase 4 2
First in 2001; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 346 is above the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 130 across the 47 interventional studies, 101 across the 14 observational. Of the 49 that completed or were terminated, 12 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 62 have an industry lead sponsor. The 10 most frequent:
United Pharmaceuticals is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
United Pharmaceuticals has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastroesophageal Reflux with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04358146United PharmaceuticalsStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR) | 2026-12-03 |
| NCT03596476Hospices Civils de LyonDiagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy | 2027-05-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Gastroesophageal Reflux with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.
The study duration is 1 month and 2 days. It is possible to add 2 additional months (optional).
The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up of 2 months (form D30 to D90).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
new thickened infant formula containing fibres
Other: Experimental Infant formula
infant formula thickened with locust bean
Other: Infant formula thickened with locust bean gum
Exclusive formula feeding with the new infant formula thickened with fibers
Exclusive formula feeding with the formula thickened with locust bean
Frequency of regurgitation
Decrease of the daily number of regurgitation between baseline and day 14
Time frame: Day 14
Frequency of regurgitations
Change in the daily number of regurgitation between baseline and day 30 / day 90
Time frame: Day 30, Day 90
Severity of regurgitation episodes
Severity of regurgitations will be assessed using the adapted Vandenplas' score (range: 0 to 6; higher scores indicate more severe regurgitation)
Time frame: Day 14, Day 30, Day 90
Stools' frequency
Average daily stool's number
Time frame: Day 14, Day 30, Day 90
Stools' consistency
The Amsterdam Infant Stool Scale (AISS) (consistency categories: A \[watery\] to D \[hard\]; higher categories indicate firmer stools)
Time frame: Day 14, Day 30, Day 90
Frequency of diarrhea
Frequency : Occurence of diarrhea
Time frame: Day 14, Day 30, Day 90
Severity of diarrhea
Severity of diarrhea assessed using a study-specific score calculated as the sum of the products of each watery stool and its volume over 2 days (minimum score: 6; no upper limit; higher scores indicate more severe diarrhea)
Time frame: Day 14, Day 30, Day 90
Frequency of constipation
Occurence of constipation
Time frame: Day 14, Day 30, Day 90
Severity of constipation
Severity of constipation assessed using a study-specific score (range: 1 to 3; higher scores indicate more severe constipation)
Time frame: Day 14, Day 30, Day 90
Crying time
Crying time reported by parents in class (Min : Less than 10 min / Max : 3h or more)
Time frame: Day 14, Day 30, Day 90
Feeding refusal
Percentage of parents reporting feeding refusal by frequency of occurence (Never / Rarely / Sometimes / Often / Always)
Time frame: Day 14, Day 30, Day 90
Abnormal posturing
Percentage of parents reporting abnormal posturing by frequency of occurence (Never / Rarely / Sometimes / Often / Always)
Time frame: Day 14, Day 30, Day 90
Sleep quality
Percentage of parents reporting poor sleep quality (Excellent / Good / Fair / Poor)
Time frame: Day 14, Day 30, Day 90
Anthropometric parameters - Weight
Body weight measured in kilograms (kg)
Time frame: Day 14, Day 30, Day 90
Anthropometric parameters - Length
Body length measured in centimeters (cm)
Time frame: Day 14, Day 30, Day 90
Anthropometric parameters - Head circumference
Head circumference measured in centimeters (cm)
Time frame: Day 14, Day 30, Day 90
Anthropometric parameters - BMI
Body mass index calculated as kg/m²
Time frame: Day 14, Day 30, Day 90
Anthropometric parameters - Weight-for-height z-score
Weight-for-height z-score calculated according to WHO Child Growth Standards
Time frame: Day 14, Day 30, Day 90
Use of drug treatments
Frequency of use of proton-pump inhibitors, prokinetics, other GERD treatment
Time frame: Day 14, Day 30, Day 90
Parents' satisfaction
Parental satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)
Time frame: Day 14, Day 30, Day 90
Investigator's satisfaction
Investigator satisfaction assessed using a 5-point Likert scale (Very satisfied, Fairly well satisfied, Somewhat dissatisfied, Very dissatisfied, No opinion)
Time frame: Day 14, Day 30, Day 90
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.
Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 44 months is above that.
Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
United Pharmaceuticals